Cited by 773PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 129 of the 131 references it cites were found in a registry or an index.

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Polivka, Jiri, Janku, Filip·2014·Pharmacology & Therapeutics

DOI 10.1016/j.pharmthera.2013.12.004

Open this paper in CoChat — free account

Abstract

Aberrations in various cellular signaling pathways are instrumental in regulating cellular metabolism, tumor development, growth, proliferation, metastasis and cytoskeletal reorganization. The fundamental cellular signaling cascade involved in these processes, the phosphatidylinositol 3-kinase/protein kinase-B/mammalian target of rapamycin (PI3K/AKT/mTOR), closely related to the mitogen-activated protein kinase (MAPK) pathway, is a crucial and intensively explored intracellular signaling pathway in tumorigenesis. Various activating mutations in oncogenes together with the inactivation of tumor suppressor genes are found in diverse malignancies across almost all members of the pathway. Substantial progress in uncovering PI3K/AKT/mTOR alterations and their roles in tumorigenesis has enabled the development of novel targeted molecules with potential for developing efficacious anticancer treatment. Two approved anticancer drugs, everolimus and temsirolimus, exemplify targeted inhibition of PI3K/AKT/mTOR in the clinic and many others are in preclinical development as well as being tested in early clinical trials for many different types of cancer. This review focuses on targeted PI3K/AKT/mTOR signaling from the perspective of novel molecular targets for cancer therapy found in key pathway members and their corresponding experimental therapeutic agents. Various aberrant prognostic and predictive biomarkers are also discussed and examples are given. Novel approaches to PI3K/AKT/mTOR pathway inhibition together with a better understanding of prognostic and predictive markers have the potential to significantly improve the future care of cancer patients in the current era of personalized cancer medicine.

Integrity signals

Registry

Crossref · 10.1016/j.pharmthera.2013.12.004

Cites

129 of 129 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
AMPK: a nutrient and energy sensor that maintains energy homeostasis
Hardie, D. G., Ross, F. A., & Hawley, S. A. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3311 · Cited by 4,602
Cellular survival: a play in three Akts
Datta, S. R., Brunet, A., & Greenberg, M. E. (1999) · Genes & Development · doi:10.1101/gad.13.22.2905 · Cited by 4,216
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A. F., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,448
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879
Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,874
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Targeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H.-L. M., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,785
Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers
Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K. A., Lin, H., Ligon, A. H., Langford, L. A., Baumgard, M. L., Hattier, T., Davis, T., et al. (1997) · Nature Genetics · doi:10.1038/ng0497-356 · Cited by 2,742
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress
Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., & Cantley, L. C. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308061100 · Cited by 1,797
The emerging mechanisms of isoform-specific PI3K signalling
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2882 · Cited by 1,767
Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648
Identification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C. L., Donoho, G. P., Briggs, S., Robbins, C. M., Hostetter, G. H., Boguslawski, S. J., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,322
PTEN and the PI3-Kinase Pathway in Cancer
Chalhoub, N., & Baker, S. J. (2008) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092311 · Cited by 1,281
Efficacy and safety of sirolimus in lymphangioleiomyomatosis
McCormack, F. X., Inoue, Y., Moss, J., Singer, L. G., Strange, C., Nakata, K., Barker, A. F., Chapman, J. T., Brantly, M. L., Stocks, J. M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1100391 · Cited by 1,099
Role of Translocation in the Activation and Function of Protein Kinase B
Andjelkovic, M., Alessi, D. R., Meier, R., Fernandez, A., Lamb, N. J. C., Frech, M., Cron, P., Cohen, P., Lucocq, J. M., & Hemmings, B. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.50.31515 · Cited by 1,051
Crystal Structure of the PTEN Tumor Suppressor
Lee, J., Yang, H., Georgescu, M.-M., Cristofano, A. D., Maehama, T., Shi, Y., Dixon, J. E., Pandolfi, P. P., & Pavletich, N. P. (1999) · Cell · doi:10.1016/s0092-8674(00)81663-3 · Cited by 1,032
The PTEN–PI3K pathway: of feedbacks and cross-talks
Carracedo, A., & Pandolfi, P. P. (2008) · Oncogene · doi:10.1038/onc.2008.247 · Cited by 908
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
Bellacosa, A., de Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Autophagy as a target for anticancer therapy
Jankú, F., McConkey, D. J., Hong, D. S., & Kurzrock, R. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.71 · Cited by 814
Development of PI3K inhibitors: lessons learned from early clinical trials
Rodon, J. A., Dienstmann, R., Serra, V., & Tabernero, J. M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.10 · Cited by 787
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.
Cheng, J. Q., Godwin, A. K., Bellacosa, A., Taguchi, T., Franke, T. F., Hamilton, T. C., Tsichlis, P. N., & Testa, J. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9267 · Cited by 737
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Bendell, J. C., Rodon, J. A., Burris, H. A., de Jonge, M. J. A., Verweij, J., Birle, D. C., Demanse, D., Buck, S. S. D., Ru, Q. C., Peters, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 703
Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S., Zhang, J., Signoretti, S., Loda, M. F., Roberts, T. M., et al. (2008) · Nature · doi:10.1038/nature07091 · Cited by 702
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al‐Ahmadie, H. A., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 697
Class I PI3K in oncogenic cellular transformation
Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 612
Deregulated Akt3 Activity Promotes Development of Malignant Melanoma
Stahl, J. M., Sharma, A. K., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M., KESTER, M. A., Sandirasegarane, L., & Robertson, G. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1399 · Cited by 595
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Lui, V. W. Y., Hedberg, M. L., Li, H., Vangara, B. S., Pendleton, K. P., Zeng, Y., Lu, Y., Zhang, Q., Du, Y., Gilbert, B. R., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0103 · Cited by 594
LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug Phenformin
Shackelford, D. B., Abt, E., Gerken, L., Vasquez, D. S., Seki, A., Leblanc, M., Wei, L., Fishbein, M. C., Czernin, J., Mischel, P. S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.008 · Cited by 585
The Structure of a Human p110α/p85α Complex Elucidates the Effects of Oncogenic PI3Kα Mutations
Huang, C., Mandelker, D. L., Schmidt‐Kittler, O., Samuels, Y., Velculescu, V. E., Kinzler, K. W., Vogelstein, B., Gabelli, S. B., & Amzel, L. M. (2007) · Science · doi:10.1126/science.1150799 · Cited by 564
The Gβγ Sensitivity of a PI3K Is Dependent upon a Tightly Associated Adaptor, p101
Stephens, L., Eguinoa, A., Erdjument‐Bromage, H., Lui, M. L., Cooke, F. T., Coadwell, J., Smrcka, A., Thelen, M., Cadwallader, K. A., Tempst, P., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80187-7 · Cited by 557
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Yap, T. A., Li, Y., Patnaik, A., Fearen, I., Olmos, D., Papadopoulos, K. P., Baird, R. D., Delgado, L., Taylor, A. B., Lupinacci, L. C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5263 · Cited by 540
AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer
Vasudevan, K. M., Barbie, D. A., Davies, M. A., Rabinovsky, R., McNear, C. J., Kim, J. J., Hennessy, B. T., Tseng, H., Pochanard, P., Kim, S. Y., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.012 · Cited by 522
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
Furet, P., Guagnano, V., Fairhurst, R. A., Imbach, P. A., Bruce, I., Knapp, M. S., Fritsch, C. M., Blasco, F., Blanz, J., Aichholz, R., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.007 · Cited by 492
Rheb fills a GAP between TSC and TOR
Manning, B. (2003) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2003.09.003 · Cited by 483
High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability
Cheung, L. W. T., Hennessy, B. T., Li, J., Yu, S., Myers, A. P., Djordjevic, B., Lu, Y., Stemke‐Hale, K., Dyer, M. D., Zhang, F., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0039 · Cited by 483
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Burris, H. A. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2043-3 · Cited by 454
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells
Knuefermann, C., Lü, Y., Liu, B., Jin, W., Liang, K., Wu, L., Schmidt, M., Mills, G. B., Mendelsohn, J. M., & Fan, Z. (2003) · Oncogene · doi:10.1038/sj.onc.1206394 · Cited by 452
Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms
Zhao, L., & Vogt, P. K. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712169105 · Cited by 449
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations
Jankú, F., Wheler, J. J., Westin, S. N., Moulder, S., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido‐Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 448
mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling
Rodrik-Outmezguine, V. S., Chandarlapaty, S., Pagano, N. C., Poulikakos, P. I., Scaltriti, M., Moskatel, E., Baselga, J., Guichard, S., & Rosen, N. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0085 · Cited by 442
Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function
Jaber, N. L., Dou, Z., Chen, J., Catanzaro, J. M., Jiang, Y.-P., Ballou, L. M., Selinger, E. S., Ouyang, X., Lin, R. Z., Zhang, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112848109 · Cited by 399
Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors
Wagner, A. J., Malinowska-Kołodziej, I., Morgan, J. A., Qin, W., Fletcher, C. D. �., Vena, N., Ligon, A. H., Antonescu, C. R., Ramaiya, N. H., Demetri, G. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.2981 · Cited by 399
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Markman, B., Dienstmann, R., & Tabernero, J. M. (2010) · Oncotarget · doi:10.18632/oncotarget.188 · Cited by 357
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
Nicolantonio, F. D., Arena, S., Tabernero, J. M., Grosso, S., Molinari, F., Macarulla, T. M., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci37539 · Cited by 348
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Jankú, F., Tsimberidou, A. M., Garrido‐Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 333
A Secreted PTEN Phosphatase That Enters Cells to Alter Signaling and Survival
Hopkins, B. D., Fine, B. M., Steinbach, N., Dendy, M., Rapp, Z., Shaw, J. M., Pappas, K., Yu, J. S., Hodakoski, C., Mense, S. M., et al. (2013) · Science · doi:10.1126/science.1234907 · Cited by 325
The Tumor Suppressor PTEN Is Exported in Exosomes and Has Phosphatase Activity in Recipient Cells
Putz, U., Howitt, J. A., Doan, A., Goh, C., Low, L., Silke, J., & Tan, S. (2012) · Science Signaling · doi:10.1126/scisignal.2003084 · Cited by 316
Evidence That Lymphangiomyomatosis Is Caused by TSC2 Mutations: Chromosome 16p13 Loss of Heterozygosity in Angiomyolipomas and Lymph Nodes from Women with Lymphangiomyomatosis
Smolarek, T. A., Wessner, L. L., McCormack, F. X., Mylet, J. C., Menon, A. G., & Henske, E. P. (1998) · The American Journal of Human Genetics · doi:10.1086/301804 · Cited by 312
PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
Jankú, F., Wheler, J. J., Naing, A., Falchook, G. S., Hong, D. S., Stepanek, V. M. T., Fu, S., Piha-Paul, S. A., Lee, J. J., Luthra, R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1726 · Cited by 303
Frequent Inactivation of PTEN by Promoter Hypermethylation in Microsatellite Instability-High Sporadic Colorectal Cancers
Goel, A., Arnold, C. N., Niedzwiecki, D., Carethers, J. M., Dowell, J. M., Wasserman, L., Compton, C., Mayer, R. J., Bertagnolli, M. M., & Boland, C. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-2401-2 · Cited by 302
Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Lin, J. M., Sampath, D., Nannini, M., Lee, B. B., Degtyarev, M. Y., Oeh, J., Savage, H. M., Guan, Z., Hong, R., Kassees, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3072 · Cited by 295
Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
Ihle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D. R., Mills, G. B., Dent, P., Kirkpatrick, D. L., & Powis, G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6656 · Cited by 275
A novel AKT3 mutation in melanoma tumours and cell lines
Davies, M. A., Stemke‐Hale, K., Tellez, C. S., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 268
Regulation of phosphoinositide 3-kinase expression in health and disease.
Kok, K., Geering, B., & Vanhaesebroeck, B. (2009) · TIBS -Trends in Biochemical Sciences. Regular ed · doi:10.1016/j.tibs.2009.01.003 · Cited by 246
Discovery of 4-Amino- N -[(1 S )-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7 H -pyrrolo[2,3- d ]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases
Addie, M., Ballard, P. G., Buttar, D., Crafter, C., Currie, G. S., Davies, B. R., Debreczeni, J. E., Dry, H., Dudley, P., Greenwood, R. D. R., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301762v · Cited by 245
Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors
Carretero, J., Shimamura, T., Rikova, K., Jackson, A. L., Wilkerson, M. D., Borgman, C. L., Buttarazzi, M., Sanofsky, B. A., McNamara, K. L., Brandstetter, K. A., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.026 · Cited by 245
Akt inhibitors in clinical development for the treatment of cancer
Pal, S. K., Reckamp, K. L., Yu, H., & Figlin, R. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.520701 · Cited by 234
GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
Wallin, J. J., Edgar, K. A., Guan, J., Berry, M., Prior, W. W., Lee, L. B., Lesnick, J., Lewis, C. T., Nonomiya, J., Pang, J., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0446 · Cited by 231
Promoter methylation of the PTEN gene is a common molecular change in breast cancer
García, J. M., Silva, J., Peña, C., García‐Barberán, V., Rodríguez, R., Cruz, M. Á., Cantos, B., Provencio, M., España, P., & Bonilla, F. (2004) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20062 · Cited by 224
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
Sato, T., Nakashima, A., Guo, L., Coffman, K., & Tamanoi, F. (2010) · Oncogene · doi:10.1038/onc.2010.28 · Cited by 223
PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia
Hayes, M. P., Wang, H., Espinal-Witter, R., Douglas, W., Solomon, G. J., Baker, S. J., & Ellenson, L. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1375 · Cited by 218
Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
Pike, K. G., Malagu, K., Hummersone, M., Menear, K. A., Duggan, H. M. E., Gomez, S., Martin, N. M. B., Ruston, L., Pass, S. L., & Pass, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.019 · Cited by 214
Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin
Bhagwat, S. V., Gokhale, P. C., Crew, A. P. A., Cooke, A., Yao, Y., Mantis, C., Kahler, J., Workman, J. E., Bittner, M., Dudkin, L., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1099 · Cited by 203
New Insights into mTOR Signaling: mTORC2 and Beyond
Alessi, D. R., Pearce, L. R., & García‐Martínez, J. M. (2009) · Science Signaling · doi:10.1126/scisignal.267pe27 · Cited by 193
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
Weigelt, B., Warne, P. H., & Downward, J. (2011) · Oncogene · doi:10.1038/onc.2011.42 · Cited by 191
Diverse Mechanisms of AKT Pathway Activation in Human Malignancy
Cheung, M., & Testa, J. R. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313030002 · Cited by 185
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
Hong, D. S., Bowles, D. W., Falchook, G. S., Messersmith, W. A., George, G. C., O’Bryant, C. L., Vo, A. C. H., Klucher, K. M., Herbst, R. S., Eckhardt, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0714 · Cited by 171
Functional Characterization of an Isoform-Selective Inhibitor of PI3K-p110β as a Potential Anticancer Agent
Ni, J., Liu, Q., Xie, S., Carlson, C. B., Von, T., Vogel, K. W., Riddle, S., Benes, C. H., Eck, M. J., Roberts, T. M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0003 · Cited by 163
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
Prasad, G., Sottero, T. L., Yang, X., Mueller, S., James, C. D., Weiss, W. A., Polley, M. Y., Ozawa, T., Berger, M. S., Aftab, D. T., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq193 · Cited by 156
mTOR kinase inhibitors as potential cancer therapeutic drugs
Sun, S. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.06.017 · Cited by 152
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia
Wiestner, A. U. (2012) · Blood · doi:10.1182/blood-2012-05-423194 · Cited by 151
ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer
Stern, D. F. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9083-7 · Cited by 150
THE AMERICAN SOCIETY OF HEMATOLOGY
Alexander, W. (2009) · Blood · doi:10.1182/blood.v114.22.r23.r23 · Cited by 146
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
Mahadevan, D., Chiorean, E. G., Harris, W. B., Hoff, D. D. V., Stejskal-Barnett, A., Qi, W., Anthony, S. P., Younger, A., Rensvold, D., Cordova-Marks, F. M., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.06.027 · Cited by 136
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
Naing, A., Aghajanian, C. A., Raymond, É., Olmos, D., Schwartz, G., Oelmann, E. M., Grinsted, L. M., Burke, W., Taylor, R., Kaye, S. B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.368 · Cited by 134
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition
Mahoney, C., Choudhury, B., Davies, H. R., Edkins, S., Greenman, C., van Haaften, G. W., Mironenko, T., Santarius, T., Stevens, C., Stratton, M. R., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604886 · Cited by 128
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
Zeng, Z., Shi, Y. X., Tsao, T., Qiu, Y., Kornblau, S. M., Baggerly, K., Liu, W., Jessen, K., Liu, Y., Kantarjian, H. M., et al. (2012) · Blood · doi:10.1182/blood-2011-11-393934 · Cited by 128
Lkb1inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy
Contreras, C. M., Akbay, E. A., Gallardo, T. D., Haynie, J. M., Sharma, S. V., Tagao, O., Bardeesy, N. M., Takahashi, M., Settleman, J., Wong, K., et al. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.004440 · Cited by 125
Isolation of DNA Sequences Amplified at Chromosome 19q13.1–q13.2 Including theAKT2Locus in Human Pancreatic Cancer
Miwa, W., Yasuda, J., Murakami, Y., Yashima, K., Sugano, K., Sekine, T., Kono, A., Egawa, S., Yamaguchi, K. D., Hayashizaki, Y., et al. (1996) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.1280 · Cited by 123
Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia
Janes, M. R., Vu, C., Mallya, S., Shieh, M., Limon, J. J., Li, L., Jessen, K., Martin, M., Ren, P., Lilly, M. B., et al. (2012) · Leukemia · doi:10.1038/leu.2012.276 · Cited by 110
INPP4B: the New Kid on the PI3K Block
Agoulnik, I., Hodgson, M., Bowden, W. A., & Ittmann, M. (2011) · OncoTarget · doi:10.18632/oncotarget.260 · Cited by 110
PTEN at a glance
Shi, Y., Paluch, B. E., Wang, X., & Jiang, X. (2012) · Journal of Cell Science · doi:10.1242/jcs.093765 · Cited by 106
Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH
橋本, 毅., Mori, N., Tamesa, T., Okada, T., Kawauchi, S., Oga, A., Furuya, T., Tangoku, A., Oka, M., & Sasaki, K. (2004) · Modern Pathology · doi:10.1038/modpathol.3800107 · Cited by 101
PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
Jankú, F., Wheler, J. J., Naing, A., Stepanek, V. M. T., Falchook, G. S., Fu, S., Garrido‐Laguna, I., Tsimberidou, A. M., Piha-Paul, S. A., Moulder, S., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.716 · Cited by 99
Mutations in the humanLKB1/STK11gene
Launonen, V. (2005) · Human Mutation · doi:10.1002/humu.20222 · Cited by 98
1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas
Ichimura, K., Vogazianou, A. P., Liu, L., Pearson, D. M., Bäcklund, L. M., Plant, K., Baird, K., Langford, C. F., Gregory, S. G., & Collins, V. P. (2007) · Oncogene · doi:10.1038/sj.onc.1210848 · Cited by 97
The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/ Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance
Hoang, B. Q., Benavides, A., Shi, Y., Yang, Y., Frost, P., Gera, J., & Lichtenstein, A. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304626 · Cited by 78
Selective Inhibition of Phosphoinositide 3-Kinase p110α Preserves Lymphocyte Function*
So, L., Yea, S., Oak, J., Lu, M., Manmadhan, A., Ke, Q. H., Janes, M. R., Kessler, L., Kucharski, J. M., Li, L.-S., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.379446 · Cited by 72
Emerging Treatments in the Management of Tuberous Sclerosis Complex
Kohrman, M. H. (2012) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2012.02.015 · Cited by 66
Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
Juric, D., Rodon, J. A., Gonzalez-Angulo, A. M., Burris, H. A., Bendell, J. C., Berlin, J. D., Middleton, M. R., Bootle, D., Boehm, M., Schmitt, A., et al. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-ct-01 · Cited by 62
New molecularly targeted therapies for glioblastoma multiforme.
Polívka, J., Polívka, J., Rohan, V., Topolčan, O., & Ferda, J. (2012) · PubMed · Cited by 59
Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms
Pymar, L. S., Platt, F. M., Askham, J. M., Morrison, E. E., & Knowles, M. A. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn098 · Cited by 58
Regression of subependymal giant cell astrocytomas with RAD001 (Everolimus) in tuberous sclerosis complex
Yalon, M., Ben‐Sira, L., Constantini, S., & Toren, A. (2010) · Child s Nervous System · doi:10.1007/s00381-010-1222-y · Cited by 50
2011 ASCO Annual Meeting
上野, 秀., & 上野, 誠. (2011) · Medical Entomology and Zoology · Cited by 47
GS-1101: A Delta-Specific PI3K Inhibitor in Chronic Lymphocytic Leukemia
Macias‐Perez, I., & Flinn, I. W. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0142-1 · Cited by 47
Lovastatin Induces Multiple Stress Pathways Including LKB1/AMPK Activation That Regulate Its Cytotoxic Effects in Squamous Cell Carcinoma Cells
Ma, L., Niknejad, N., Gorn‐Hondermann, I., Dayekh, K., & Dimitroulakos, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046055 · Cited by 47
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
Blaser, B., Waselle, L., Dormond-Meuwly, A., Dufour, M., Roulin, D., Demartines, N., & Dormond, O. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-86 · Cited by 47
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia.
Wiestner, A. U. (2012) · PubMed · doi:10.1182/asheducation-2012.1.88 · Cited by 45
Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma
Kang, S., Seo, S., Chang, H. J., Yoo, C. W., Park, S. Y., & Dong, S. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01172.x · Cited by 43
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
Ogita, S., & LoRusso, P. M. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0176-7 · Cited by 40
BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
Juric, D., Rodon, J. A., Gonzalez-Angulo, A., Burris, H. A., Bendell, J. C., Berlin, J., Middleton, M. R., Bootle, D., Boehm, M., Schmitt, A., et al. (2012) · Cancer Research · Cited by 39
Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex
Cappellano, A. M., Senerchia, A. A., Adolfo, F., Paiva, P. M., Pinho, R. S., Covic, A. N., Cavalheiro, S., & Saba, N. (2013) · Child s Nervous System · doi:10.1007/s00381-013-2170-0 · Cited by 33
Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC)
Juric, D., Argilés, G., Burris, H., Gonzalez-Angulo, A., Saura, C., Quadt, C., Douglas, M., Demanse, D., Buck, S., & Baselga, J. M. (2012) · Cancer Research · doi:10.1158/0008-5472.sabcs12-p6-10-07 · Cited by 31
A rationale for mTOR inhibitors as chemoprevention agents in Peutz-Jeghers syndrome
Kuwada, S. K., & Burt, R. W. (2011) · Familial Cancer · doi:10.1007/s10689-011-9471-9 · Cited by 27
Mutation analysis of the human homologue ofdrosophila patched and the xeroderma pigmentosum complementation group A genes in squamous cell carcinomas of the skin
Eklund, L. K., Lindström, E., Undén, A. B., Lundh-Rozell, B., Ståhle‐Bäckdahl, M., Zaphiropoulos, P. G., Toftgård, R., & Söderkvist, P. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199802)21:2 · Cited by 23
Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program
Reynolds, C. P., Kang, M. H., Carol, H., Lock, R. B., Gorlick, R. G., Kolb, E. A., Kurmasheva, R. T., Keir, S. T., Maris, J. M., Billups, C. A., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24301 · Cited by 20
Response of Lymphangioleiomyomatosis to a Mammalian Target of Rapamycin Inhibitor (Temsirolimus) –Based Treatment
Piha-Paul, S. A., Hong, D. S., & Kurzrock, R. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.5928 · Cited by 14
Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Cheng, H., Merika, E., Syrigos, K., & Saif, M. W. (2011) · PubMed · Cited by 14
PTEN assessment and PI3K/mTOR inhibitors: Importance of simultaneous assessment of MAPK pathway aberrations.
Jankú, F., Broaddus, R. R., Bakkar, R. M., Hong, D. S., Stepanek, V. M. T., Naing, A., Falchook, G. S., Fu, S., Wheler, J. J., Piha-Paul, S. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.10510 · Cited by 12
Pills of PTEN? In and out for tumor suppression
Papa, A., Chen, M., & Pandolfi, P. P. (2013) · Cell Research · doi:10.1038/cr.2013.103 · Cited by 11
Studies of NVP-BEZ235 in Melanoma
Sznol, J. A., Jilaveanu, L. B., & Kluger, H. M. (2013) · Current Cancer Drug Targets · doi:10.2174/1568009611313020006 · Cited by 10
Cowden syndrome (multiple hamartoma syndrome)
Aslam, A. M., & Coulson, I. H. (2013) · Clinical and Experimental Dermatology · doi:10.1111/ced.12140 · Cited by 9
PD09-05: SU2C Phase Ib Study of pan-PI3K Inhibitor BKM120 Plus Aromatase Inhibitor Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC).
Mayer, I. A., Balko, J. M., Kuba, M., Sanders, M., Yap, J. T., Li, Y., Winer, E. P., & Arteaga, C. (2011) · Cancer Research · doi:10.1158/0008-5472.sabcs11-pd09-05 · Cited by 7
Bringing target-matched PI3King from the bench to the clinic
Jankú, F. (2013) · Cell Cycle · doi:10.4161/cc.25118 · Cited by 6
A phase I study of BKM120, a novel oral selective phosphatidylinositol-3-kinase (PI3K) inhibitor, in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer.
Nagaraj, G., Ma, C. X., Luo, J. R., & Ellis, M. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.tps664 · Cited by 5
246 Aberrations in PIK3CA, PTEN, and MAPK (KRAS, NRAS, BRAF) in 1,656 Patients and Experience with Early-phase Protocols with PI3K/AKT/mTOR Inhibitors
Jankú, F., Hong, D. S., Fu, S., Piha-Paul, S. A., Naing, A., Falchook, G. S., Tsimberidou, A. M., Stepanek, V. M. T., Wheler, J. J., & Kurzrock, R. (2012) · European Journal of Cancer · doi:10.1016/s0959-8049(12)72044-0 · Cited by 4

Research works printed but not linked: 1

Janku, 2011, Loss of PTEN expression in patients treated with PI3K/AKT/mTOR signaling pathway inhibitors, Cancer Res, 71

Sorted by citations

Targeting the PI3K pathway in cancer: are we making headway?
Janku, F., Yap, T. A., & Meric-Bernstam, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.28 · Cited by 1,033
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C. I., Drulă, R., Gulei, D., Ráduly, L., Alexandru Vasile, R. U. S. U., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 940
RETRACTED ARTICLE: Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression via the AKT1/mTOR pathway
Zhang, X., Wang, S., Wang, H., Cao, J., Huang, X., Chen, Z., Xu, P., Sun, G., Xu, J., Lv, J., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0935-5 · Cited by 832
Retracted
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 818
Health benefits of polyphenols: A concise review
Rana, A., Samtiya, M., Dhewa, T., Mishra, V., & Aluko, R. E. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14264 · Cited by 840

See all 773

Authors: Polivka, J., & Janku, F.
Venue: Pharmacology & Therapeutics
Publisher: Elsevier BV
Published: 2014-05
Volume: 142
Issue: 2
Pages: 164-175
ISSN: 0163-7258 (ISSN-L)
DOI: 10.1016/j.pharmthera.2013.12.004
OpenAlex: W2132052921
Cited by: 765
References: 131
Citations by year: 2026: 20 · 2025: 31 · 2024: 41 · 2023: 71 · 2022: 56 · 2021: 90 · 2020: 80 · 2019: 103 · 2018: 63 · 2017: 71 · 2016: 51 · 2015: 59 · 2014: 28
FWCI: 4.39
Type: journal article
Language: en
Open access: closed
Locations: Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: PI3K/AKT/mTOR pathway, targeted cancer therapy, molecular targets, PI3K inhibitors, mTOR inhibitors, everolimus, temsirolimus, MAPK signaling, oncogenic mutations, tumor suppressor, prognostic factors, predictive biomarkers, precision oncology, carcinogenesis
MeSH terms: Phosphoinositide-3 Kinase Inhibitors, Animals, Antineoplastic Agents, Humans, Neoplasms, Drug Design, Signal Transduction, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, Phosphatidylinositol 3-Kinase, TOR Serine-Threonine Kinases, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks